Username

Password

Forgot Password?

Preview

Sign-in free and Explore the Exciting World of BiomedExperts:

Over 1.500.000 Profiles
More than 1.800 Organizations worldwide
State of the Art Network Visualizations

Manage your own Profile
Locate Experts in your Country/Region
Locate Experts in your 1. and 2. Level Network
Connect to Experts Worldwide

NetworkView

Hans-Peter Hartung

This is a preview profile on BiomedExperts - the first literature-based scientific social network. It brings the right researchers together and allows them to collaborate online. Collexis and Dell provide the BiomedExperts network of +1.5 Million pre-calculated profiles free of charge to researchers worldwide.

Research Profile (preview)

Disorders

Living Beings

Anatomy

Chemicals & Drugs

Concepts & Ideas

Magnetic Resonance Imaging

Physiology

Lymphocyte Activation

Sign-in to see full Profile

Network (preview)

Co-Publications
Name
91
Kieseier, Bernd
87
Toyka, Klaus
34
Gold, Ralf
33
Jung, Stefan
32
Archelos, Juan
24
Fazekas, Franz
24
Hemmer, Bernhard
23
Stüve, Olaf
21
Wiendl, Heinz
19
Neuhaus, Oliver
18
Zielasek, Jürgen
16
Lehmann, Helmar
14
Giegerich, G
14
Strasser-Fuchs, Siegrid
10
Auer-Grumbach, Michaela

Sign-in to see all Coauthors

Publications

TOP 3
zu Horste Gerd Meyer; Heidenreich Holger; Lehmann Helmar C; Ferrone Soldano; Hartung Hans-Peter; Wiendl Heinz; Kieseier Bernd C
Expression of antigen processing and presenting molecules by Schwann cells in inflammatory neuropathies.
Aktas Orhan; Hartung Hans-Peter
Neuromyelitis and more: the unfolding spectrum of aquaporin 4-related neurological diseases.
Lehmann Helmar C; Hartung Hans-Peter
Variants of Guillain-Barré syndrome: low incidence but high impact.

Sign-in to see all Publications

Sign in free and see...

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the visualized research activity
of experts around the globe

Sign-in to see more

Geonetwork of Hans-Peter Hartung (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

Sign-in to see more

All Publications

2010: zu Horste Gerd Meyer; Heidenreich Holger; Lehmann Helmar C; Ferrone Soldano; Hartung Hans-Peter; Wiendl Heinz; Kieseier Bernd C
Expression of antigen processing and presenting molecules by Schwann cells in inflammatory neuropathies.
Glia 2010;58(1):80-92.
2009: Aktas Orhan; Hartung Hans-Peter
Neuromyelitis and more: the unfolding spectrum of aquaporin 4-related neurological diseases.
Journal of neurology 2009;256(11):1906-8.
2009: Lehmann Helmar C; Hartung Hans-Peter
Variants of Guillain-Barré syndrome: low incidence but high impact.
Journal of neurology 2009;256(11):1909-10.
2009: Hartung Hans-Peter; Aktas Orhan
Bleak prospects for primary progressive multiple sclerosis therapy: downs and downs, but a glimmer of hope.
Annals of neurology 2009;66(4):429-32.
2009: Otto Frauke; Illes Sebastian; Opatz Jessica; Laryea Maurice; Theiss Stephan; Hartung Hans-Peter; Schnitzler Alfons; Siebler Mario; Dihné Marcel
Cerebrospinal fluid of brain trauma patients inhibits in vitro neuronal network function via NMDA receptors.
Annals of neurology 2009;66(4):546-55.
2009: Kieseier Bernd C; Wiendl Heinz; Hartung Hans-Peter; Stüve Olaf
The future of multiple sclerosis therapy.
Pharmacological research : the official journal of the Italian Pharmacological Society 2009;60(4):207-11.
2009: Hartung H-P; Warnke C; Hohlfeld R; Kieseier B C
[Progressive multifocal leukoencephalopathy. Undesirable side effect of immunotherapy]
Der Nervenarzt 2009;80(10):1143-4, 1146-8, 1150-3.
2009: Menge T; Schloot N C; Schott M; Hemmer B; Wiendl H; Roden M; Hartung H-P; Kieseier B C
Interferon beta treatment does not induce organ-specific autoantibodies in multiple sclerosis.
Neurology 2009;73(11):900-2.
2009: Kremer David; Heinen André; Jadasz Janusz; Göttle Peter; Zimmermann Kristin; Zickler Philipp; Jander Sebastian; Hartung Hans-Peter; Küry Patrick
p57kip2 is dynamically regulated in experimental autoimmune encephalomyelitis and interferes with oligodendroglial maturation.
Proceedings of the National Academy of Sciences of the United States of America 2009;106(22):9087-92.
2009: Hofstetter Harald H; Stüve Olaf; Hartung Hans-Peter
Is 1+1 0, 1, 2, or 11? Arithmetics of antiinflammatory agents in autoimmunity.
Experimental neurology 2009;217(1):4-6.
2009: Hofstetter Hh; Gold R; Hartung H-P
Th17 Cells in MS and Experimental Autoimmune Encephalomyelitis.
International MS journal / MS Forum 2009;16(1):12-8.
2009: Warnke C; Kieseier B C; Zettl U; Hartung H-P
[Possibilities and risks of the monoclonal antibody alemtuzumab as a new treatment option for multiple sclerosis]
Der Nervenarzt 2009;80(4):468-74.
2009: Lehmann Helmar C; Köhne Angelika; Bernal Fabian; Jangouk Parastoo; Meyer Zu Hörste Gerd; Dehmel Thomas; Hartung Hans-Peter; Previtali Stefano C; Kieseier Bernd C
Matrix metalloproteinase-2 is involved in myelination of dorsal root ganglia neurons.
Glia 2009;57(5):479-89.
2009: Hartung Hans-Peter
High-dose, high-frequency recombinant interferon beta-1a in the treatment of multiple sclerosis.
Expert opinion on pharmacotherapy 2009;10(2):291-309.
2009: Menge T; Büdingen H-C; Dalakas M C; Kieseier B C; Hartung H-P
[Targeting B cells in multiple sclerosis. Current concepts and strategies]
Der Nervenarzt 2009;80(2):190-8.
2009: Wellen Jennifer; Walter Janine; Jangouk Parastoo; Hartung Hans-Peter; Dihné Marcel
Neural precursor cells as a novel target for interferon-beta.
Neuropharmacology 2009;56(2):386-98.
2009: Hofstetter Harald H; Smolianov Vsevolod; Hartung Hans-Peter
Untired regulatory T cells: untying fatigue from T cell regulation in multiple sclerosis.
European neurology 2009;62(6):327-9.
2009: Illes Sebastian; Theiss Stephan; Hartung Hans-Peter; Siebler Mario; Dihné Marcel
Niche-dependent development of functional neuronal networks from embryonic stem cell-derived neural populations.
BMC neuroscience 2009;10():93.
2009: Warnke Clemens; Meyer Zu Hörste Gerd; Hartung Hans-Peter; Stüve Olaf; Kieseier Bernd C
Review of teriflunomide and its potential in the treatment of multiple sclerosis.
Neuropsychiatric disease and treatment 2009;5():333-40.
2009: Zickler Philipp; Hartung Hans-Peter; Janssen Hendrik
'Bubbles in the brain': retrograde venous air embolism in the cavernous sinus.
European neurology 2009;61(5):318.
2008: Hofstetter Harald H; Stüve Olaf; Hartung Hans-Peter
Fine-tuning the homeostasis of regulatory T cells: new mechanism of immunomodulatory therapy in multiple sclerosis.
Archives of neurology 2008;65(11):1417-8.
2008: Kieseier Bernd C; Meyer Zu Hörste Gerd; Lehmann Helmar C; Gold Ralf; Hartung Hans-Peter
Intravenous immunoglobulins in the treatment of immune neuropathies.
Current opinion in neurology 2008;21(5):555-62.
2008: Lehmann Helmar C; Hartung Hans-Peter; Meyer Zu Hörste Gerd; Kieseier Bernd C
Plasma exchange in immune-mediated neuropathies.
Current opinion in neurology 2008;21(5):547-54.
2008: Hartung Hans-Peter; Kieseier Bernd C
Advances in biotechnology and novel insights into pathophysiology have contributed to an increased understanding of the pathomechanisms of diseases affecting the peripheral nervous system.
Current opinion in neurology 2008;21(5):517-8.
2008: Heinen André; Kremer David; Hartung Hans-Peter; Küry Patrick
p57 kip2's role beyond Schwann cell cycle control.
Cell cycle (Georgetown, Tex.) 2008;7(18):2781-6.
2008: Leussink Verena I; Lehmann Helmar C; Meyer zu Hörste Gerd; Hartung Hans-Peter; Stüve Olaf; Kieseier Bernd C
Rituximab induces clinical stabilization in a patient with fulminant multiple sclerosis not responding to natalizumab. Evidence for disease heterogeneity.
Journal of neurology 2008;255(9):1436-8.
2008: Hoffmann Steve; Cepok Sabine; Grummel Verena; Lehmann-Horn Klaus; Hackermüller Jörg; Stadler Peter F; Hartung Hans-Peter; Berthele Achim; Deisenhammer Florian; Wassmuth Ralf; Hemmer Bernhard
HLA-DRB1*0401 and HLA-DRB1*0408 are strongly associated with the development of antibodies against interferon-beta therapy in multiple sclerosis.
American journal of human genetics 2008;83(2):219-27.
2008: Dehmel Thomas; Goebel Hans Hilmar; Hartung Hans-Peter; Lehmann Helmar; Wiendl Heinz; Kieseier Bernd C
The metalloproteinase-disintegrin ADAM10 is exclusively expressed by type I muscle fibers.
Muscle & nerve 2008;38(2):1049-51.
2008: Hofstetter Harald H; Stüve Olaf; Hartung Hans-Peter
Temporary leukocyte effects in temporal lobe epilepsy?
Experimental neurology 2008;212(2):239-41.
2008: Lehmann Helmar C; Hoffmann Felix R; Fusshoeller Andreas; Meyer zu Hörste Gerd; Hetzel Rüdiger; Hartung Hans-Peter; Schroeter Michael; Kieseier Bernd C
The clinical value of therapeutic plasma exchange in multifocal motor neuropathy.
Journal of the neurological sciences 2008;271(1-2):34-9.
2008: Hartung Hans-Peter
Advances in the understanding of the mechanism of action of IVIg.
Journal of neurology 2008;255 Suppl 3():3-6.
2008: Fazekas F; Lublin F D; Li D; Freedman M S; Hartung H P; Rieckmann P; Sørensen P Soelberg; Maas-Enriquez M; Sommerauer B; Hanna K;
Intravenous immunoglobulin in relapsing-remitting multiple sclerosis: a dose-finding trial.
Neurology 2008;71(4):265-71.
2008: Leussink Verena I; Lehmann Helmar C; Hartung Hans-Peter; Gold Ralf; Kieseier Bernd C
Type III systemic allergic reaction to natalizumab.
Archives of neurology 2008;65(6):851-2; author reply 852.
2008: Lehmann Helmar C; Hartung Hans-Peter
Complementing the therapeutic armamentarium for Miller Fisher Syndrome and related immune neuropathies.
Brain : a journal of neurology 2008;131(Pt 5):1168-70.
2008: Zohren Fabian; Toutzaris Diamandis; Klärner Viola; Hartung Hans-Peter; Kieseier Bernd; Haas Rainer
The monoclonal anti-VLA-4 antibody natalizumab mobilizes CD34+ hematopoietic progenitor cells in humans.
Blood 2008;111(7):3893-5.
2008: Meyer zu Hörste Gerd; Hu Wei; Hartung Hans-Peter; Lehmann Helmar C; Kieseier Bernd C
The immunocompetence of Schwann cells.
Muscle & nerve 2008;37(1):3-13.
2008: Menge Til; Weber Martin S; Hemmer Bernhard; Kieseier Bernd C; von Büdingen Hans-Christian; Warnke Clemens; Zamvil Scott S; Boster Aaron; Khan Omar; Hartung Hans-Peter; Stüve Olaf
Disease-modifying agents for multiple sclerosis: recent advances and future prospects.
Drugs 2008;68(17):2445-68.
2008: Stüve Olaf; Bennett Jeffrey L; Hemmer Bernhard; Wiendl Heinz; Racke Michael K; Bar-Or Amit; Hu Wei; Zivadinov Robert; Weber Martin S; Zamvil Scott S; Pacheco Maria F; Menge Til; Hartung Hans-Peter; Kieseier Bernd C; Frohman Elliot M
Pharmacological treatment of early multiple sclerosis.
Drugs 2008;68(1):73-83.
2007: Albrecht Philipp; Fröhlich Ruth; Hartung Hans-Peter; Kieseier Bernd C; Methner Axel
Optical coherence tomography measures axonal loss in multiple sclerosis independently of optic neuritis.
Journal of neurology 2007;254(11):1595-6.
2007: Lehmann H C; Hartung H-P; Kieseier B C
Leopold Ordenstein: on paralysis agitans and multiple sclerosis.
Multiple sclerosis (Houndmills, Basingstoke, England) 2007;13(9):1195-9.
2007: Cepok Sabine; von Geldern Gloria; Nolting Thorsten; Grummel Verena; Srivastava Rajneesh; Zhou Dun; Hartung Hans-Peter; Adams Ortwin; Arendt Gabriele; Hemmer Bernhard
Viral load determines the B-cell response in the cerebrospinal fluid during human immunodeficiency virus infection.
Annals of neurology 2007;62(5):458-67.
2007: Hemmer Bernhard; Hartung Hans-Peter
Toward the development of rational therapies in multiple sclerosis: what is on the horizon?
Annals of neurology 2007;62(4):314-26.
2007: Kopadze T; Dehmel T; Mylius H A; Hartung H-P; Wiendl H; Kieseier B C
Treosulfan impedes the migration of immunocompetent cells.
Journal of neurology 2007;254(10):1457-8.
2007: Saleh Andreas; Schroeter Michael; Ringelstein Adrian; Hartung Hans-Peter; Siebler Mario; Mödder Ulrich; Jander Sebastian
Iron oxide particle-enhanced MRI suggests variability of brain inflammation at early stages after ischemic stroke.
Stroke; a journal of cerebral circulation 2007;38(10):2733-7.
2007: Nessler Stefan; Boretius Susann; Stadelmann Christine; Bittner Alwina; Merkler Doron; Hartung Hans-Peter; Michaelis Thomas; Brück Wolfgang; Frahm Jens; Sommer Norbert; Hemmer Bernhard
Early MRI changes in a mouse model of multiple sclerosis are predictive of severe inflammatory tissue damage.
Brain : a journal of neurology 2007;130(Pt 8):2186-98.
2007: Neuhaus Oliver; Kieseier Bernd C; Hartung Hans-Peter
Pharmacokinetics and pharmacodynamics of the interferon-betas, glatiramer acetate, and mitoxantrone in multiple sclerosis.
Journal of the neurological sciences 2007;259(1-2):27-37.
2007: Wiendl Heinz; Kieseier Bernd C; Weissert Robert; Mylius Heidrun A; Pichlmeier Uwe; Hartung Hans-Peter; Melms Arthur; Kuker Wilhelm; Weller Michael
Treatment of active secondary progressive multiple sclerosis with treosulfan.
Journal of neurology 2007;254(7):884-9.
2007: Kieseier Bernd C; Wiendl Heinz; Hemmer Bernhard; Hartung Hans-Peter
Treatment and treatment trials in multiple sclerosis.
Current opinion in neurology 2007;20(3):286-93.
2007: Menge Til; Kieseier Bernd C; Nessler Stefan; Hemmer Bernhard; Hartung Hans-Peter; Stüve Olaf
Acute disseminated encephalomyelitis: an acute hit against the brain.
Current opinion in neurology 2007;20(3):247-54.
2007: Neuhaus Oliver; Hartung Hans-Peter
Evaluation of atorvastatin and simvastatin for treatment of multiple sclerosis.
Expert review of neurotherapeutics 2007;7(5):547-56.
2007: Lehmann Helmar C; Köhne Angelika; Meyer zu Hörste Gerd; Dehmel Thomas; Kiehl Olivia; Hartung Hans-Peter; Kastenbauer Stefan; Kieseier Bernd C
Role of nitric oxide as mediator of nerve injury in inflammatory neuropathies.
Journal of neuropathology and experimental neurology 2007;66(4):305-12.
2007: Meyer zu Hörste Gerd; Hartung Hans-Peter; Kieseier Bernd C
From bench to bedside--experimental rationale for immune-specific therapies in the inflamed peripheral nerve.
Nature clinical practice. Neurology 2007;3(4):198-211.
2007: Dehmel Thomas; Janke Angela; Hartung Hans-Peter; Goebel Hans-Hilmar; Wiendl Heinz; Kieseier Bernd C
The cell-specific expression of metalloproteinase-disintegrins (ADAMs) in inflammatory myopathies.
Neurobiology of disease 2007;25(3):665-74.
2007: Lehmann H C; Hartung H P; Hetzel G R; Kieseier B C
[Plasma exchange as a therapeutic option in neurological disorders]
Der Nervenarzt 2007;78(2):166, 168-70, 172-6.
2007: Hu W; Janke A; Ortler S; Hartung H-P; Leder C; Kieseier B C; Wiendl H
Expression of CD28-related costimulatory molecule and its ligand in inflammatory neuropathies.
Neurology 2007;68(4):277-82.
2007: von Geldern Gloria; Cepok Sabine; Nolting Thorsten; Du Yihua; Grummel Verena; Adams Ortwin; Hartung Hans-Peter; Arendt Gabriele; Hemmer Bernhard
CD8 T-cell subsets and viral load in the cerebrospinal fluid of therapy-naive HIV-infected individuals.
AIDS (London, England) 2007;21(2):250-3.
2007: Kieseier Bernd C; Hartung Hans-Peter
Interferon-beta and neuroprotection in multiple sclerosis--facts, hopes and phantasies.
Experimental neurology 2007;203(1):1-4.
2006: Zhou Dun; Srivastava Rajneesh; Nessler Stefan; Grummel Verena; Sommer Norbert; Brück Wolfgang; Hartung Hans-Peter; Stadelmann Christine; Hemmer Bernhard
Identification of a pathogenic antibody response to native myelin oligodendrocyte glycoprotein in multiple sclerosis.
Proceedings of the National Academy of Sciences of the United States of America 2006;103(50):19057-62.
2006: Kopadze Tea; Dehmel Thomas; Hartung Hans-Peter; Stüve Olaf; Kieseier Bernd C
Inhibition by mitoxantrone of in vitro migration of immunocompetent cells: a possible mechanism for therapeutic efficacy in the treatment of multiple sclerosis.
Archives of neurology 2006;63(11):1572-8.
2006: Kieseier Bernd C; Hartung Hans-Peter; Wiendl Heinz
Immune circuitry in the peripheral nervous system.
Current opinion in neurology 2006;19(5):437-45.
2006: Wiendl H; Kieseier B C; Gold R; Hohlfeld R; Bendszus M; Hartung H-P
[Revision of McDonald's new diagnostic criteria for multiple sclerosis]
Der Nervenarzt 2006;77(10):1235, 1237-45.
2006: Lehmann Helmar C; Hartung Hans-Peter; Hetzel Gerd R; Stüve Olaf; Kieseier Bernd C
Plasma exchange in neuroimmunological disorders: part 2. Treatment of neuromuscular disorders.
Archives of neurology 2006;63(8):1066-71.
2006: Lehmann Helmar C; Hartung Hans-Peter; Hetzel Gerd R; Stüve Olaf; Kieseier Bernd C
Plasma exchange in neuroimmunological disorders: Part 1: Rationale and treatment of inflammatory central nervous system disorders.
Archives of neurology 2006;63(7):930-5.
2006: Hu Wei; Dehmel Thomas; Pirhonen Jaana; Hartung Hans-Peter; Kieseier Bernd C
Interleukin 23 in acute inflammatory demyelination of the peripheral nerve.
Archives of neurology 2006;63(6):858-64.
2006: Schroeter Michael; Zickler Philipp; Denhardt David T; Hartung Hans-Peter; Jander Sebastian
Increased thalamic neurodegeneration following ischaemic cortical stroke in osteopontin-deficient mice.
Brain : a journal of neurology 2006;129(Pt 6):1426-37.
2006: Hemmer Bernhard; Nessler Stefan; Zhou Dun; Kieseier Bernd; Hartung Hans-Peter
Immunopathogenesis and immunotherapy of multiple sclerosis.
Nature clinical practice. Neurology 2006;2(4):201-11.
2006: Zhou Dun; Srivastava Rajneesh; Grummel Verena; Cepok Sabine; Hartung Hans-Peter; Hemmer Bernhard
High throughput analysis of TCR-beta rearrangement and gene expression in single T cells.
Laboratory investigation; a journal of technical methods and pathology 2006;86(3):314-21.
2006: Neuhaus Oliver; Kieseier Bernd C; Hartung Hans-Peter
Therapeutic role of mitoxantrone in multiple sclerosis.
Pharmacology & therapeutics 2006;109(1-2):198-209.
2006: Neuhaus Oliver; Kieseier Bernd C; Hartung Hans-Peter
Mitoxantrone in multiple sclerosis.
Advances in neurology 2006;98():293-302.
2005: Menge Til; Hemmer Bernhard; Nessler Stefan; Wiendl Heinz; Neuhaus Oliver; Hartung Hans-Peter; Kieseier Bernd C; Stüve Olaf
Acute disseminated encephalomyelitis: an update.
Archives of neurology 2005;62(11):1673-80.
2005: Hartung Hans-Peter; Kieseier Bernd C; Hemmer Bernhard
Purely systemically active anti-inflammatory treatments are adequate to control multiple sclerosis.
Journal of neurology 2005;252 Suppl 5():v30-7.
2005: Neuhaus Oliver; Wiendl Heinz; Kieseier Bernd C; Archelos Juan J; Hemmer Bernhard; Stüve Olaf; Hartung Hans-Peter
Multiple sclerosis: Mitoxantrone promotes differential effects on immunocompetent cells in vitro.
Journal of neuroimmunology 2005;168(1-2):128-37.
2005: Stüve Olaf; Cepok Sabine; Elias Birte; Saleh Andreas; Hartung Hans-Peter; Hemmer Bernhard; Kieseier Bernd C
Clinical stabilization and effective B-lymphocyte depletion in the cerebrospinal fluid and peripheral blood of a patient with fulminant relapsing-remitting multiple sclerosis.
Archives of neurology 2005;62(10):1620-3.
2005: Kurz Martin; Pischel Heidrun; Hartung Hans-Peter; Kieseier Bernd C
Tumor necrosis factor-alpha-converting enzyme is expressed in the inflamed peripheral nervous system.
Journal of the peripheral nervous system : JPNS 2005;10(3):311-8.
2005: Hartung Hans-Peter
Early treatment and dose optimisation BENEFIT and BEYOND.
Journal of neurology 2005;252 Suppl 3():iii44-iii50.
2005: Krapf H; Morrissey S P; Zenker O; Zwingers T; Gonsette R; Hartung H-P;
Effect of mitoxantrone on MRI in progressive MS: results of the MIMS trial.
Neurology 2005;65(5):690-5.
2005: Hartung H-P; Munschauer F; Schellekens H
Significance of neutralizing antibodies to interferon beta during treatment of multiple sclerosis: expert opinions based on the Proceedings of an International Consensus Conference.
European journal of neurology : the official journal of the European Federation of Neurological Societies 2005;12(8):588-601.
2005: Schreiner B; Kieseier B C; Hartung H-P; Hohlfeld R; Wiendl H
[Blocking adhesion molecules with natalizumab in multiple sclerosis]
Der Nervenarzt 2005;76(8):999-1005.
2005: Hemmer Bernhard; Stüve Olaf; Kieseier Bernd; Schellekens Huub; Hartung Hans-Peter
Immune response to immunotherapy: the role of neutralising antibodies to interferon beta in the treatment of multiple sclerosis.
Lancet neurology 2005;4(7):403-12.
2005: Cepok Sabine; Rosche Berit; Grummel Verena; Vogel Friederike; Zhou Dun; Sayn Joachim; Sommer Norbert; Hartung Hans-Peter; Hemmer Bernhard
Short-lived plasma blasts are the main B cell effector subset during the course of multiple sclerosis.
Brain : a journal of neurology 2005;128(Pt 7):1667-76.
2005: Neuhaus Oliver; Stüve Olaf; Archelos Juan J; Hartung Hans-Peter
Putative mechanisms of action of statins in multiple sclerosis--comparison to interferon-beta and glatiramer acetate.
Journal of the neurological sciences 2005;233(1-2):173-7.
2005: Köller Hubertus; Schroeter Michael; Kieseier Bernd C; Hartung Hans-Peter
Chronic inflammatory demyelinating polyneuropathy--update on pathogenesis, diagnostic criteria and therapy.
Current opinion in neurology 2005;18(3):273-8.
2005: Stüve O; Nessler S; Hartung H P; Hemmer B; Wiendl H; Kieseier B C
[Acute disseminated encephalomyelitis. Pathogenesis, diagnosis, treatment, and prognosis]
Der Nervenarzt 2005;76(6):701-7.
2005: Zickler Philipp; Seitz Rüdiger J; Hartung Hans-Peter; Hefter Harald
Bilateral medullary pyramid infarction.
Neurology 2005;64(10):1801.
2005: Menge Til; Hartung Hans-Peter; Stüve Olaf
Statins--a cure-all for the brain?
Nature reviews. Neuroscience 2005;6(4):325-31.
2005: Menge T; von Büdingen H-C; Zamvil S S; Hartung H-P; Kieseier B C; Stüve O
[Statins for treatment of CNS diseases. Status report from research and clinical practice]
Der Nervenarzt 2005;76(4):426-37.
2005: Köller Hubertus; Kieseier Bernd C; Jander Sebastian; Hartung Hans-Peter
Chronic inflammatory demyelinating polyneuropathy.
The New England journal of medicine 2005;352(13):1343-56.
2005: Auer-Grumbach Michaela; Schlotter-Weigel Beate; Lochmüller Hanns; Strobl-Wildemann Gertrud; Auer-Grumbach Piet; Fischer Renate; Offenbacher Hans; Zwick Ernst Bernhard; Robl Tanja; Hartl Gerald; Hartung Hans-Peter; Wagner Klaus; Windpassinger Christian;
Phenotypes of the N88S Berardinelli-Seip congenital lipodystrophy 2 mutation.
Annals of neurology 2005;57(3):415-24.
2005: Küry Patrick; Zickler Philipp; Stoll Guido; Hartung Hans-Peter; Jander Sebastian
Osteopontin, a macrophage-derived matricellular glycoprotein, inhibits axon outgrowth.
The FASEB journal : official publication of the Federation of American Societies for Experimental Biology 2005;19(3):398-400.
2005: Mitsdoerffer Meike; Schreiner Bettina; Kieseier Bernd C; Neuhaus Oliver; Dichgans Johannes; Hartung Hans-Peter; Weller Michael; Wiendl Heinz
Monocyte-derived HLA-G acts as a strong inhibitor of autologous CD4 T cell activation and is upregulated by interferon-beta in vitro and in vivo: rationale for the therapy of multiple sclerosis.
Journal of neuroimmunology 2005;159(1-2):155-64.
2005: Köller H; Neuhaus O; Schroeter M; Hartung H-P
[Myopathies under therapy with lipid-lowering agents]
Der Nervenarzt 2005;76(2):212-7.
2005: Bernal Fabian; Hartung Hans-Peter; Kieseier Bernd C
Tissue mRNA expression in rat of newly described matrix metalloproteinases.
Biological research 2005;38(2-3):267-71.
2005: Neuhaus Oliver; Stüve Olaf; Zamvil Scott S; Hartung Hans-Peter
Evaluation of HMG-CoA reductase inhibitors for multiple sclerosis: opportunities and obstacles.
CNS drugs 2005;19(10):833-41.
2004: Nickel J; Neuen-Jacob E; Saleh A; Gattermann N; Hartung H-P; Köller H
CIDP and isolated osteosclerotic myeloma.
Neurology 2004;63(12):2439.
2004: Schreiner Bettina; Mitsdoerffer Meike; Kieseier Bernd C; Chen Lieping; Hartung Hans-Peter; Weller Michael; Wiendl Heinz
Interferon-beta enhances monocyte and dendritic cell expression of B7-H1 (PD-L1), a strong inhibitor of autologous T-cell activation: relevance for the immune modulatory effect in multiple sclerosis.
Journal of neuroimmunology 2004;155(1-2):172-82.
2004: Neuhaus Oliver; Kieseier Bernd C; Klimke Ansgar; Gaebel Wolfgang; Hohlfeld Reinhard; Hartung Hans-Peter
[Cannabinoids in multiple sclerosis. Opportunity or hazard?]
Der Nervenarzt 2004;75(10):1022-6.
2004: Hartung Hans-Peter; Bar-Or Amit; Zoukos Yannis
What do we know about the mechanism of action of disease-modifying treatments in MS?
Journal of neurology 2004;251 Suppl 5():v12-v29.
2004: Kieseier Bernd C; Kiefer Reinhard; Gold Ralf; Hemmer Bernhard; Willison Hugh J; Hartung Hans-Peter
Advances in understanding and treatment of immune-mediated disorders of the peripheral nervous system.
Muscle & nerve 2004;30(2):131-56.
2004: Neuhaus Oliver; Kieseier Bernd C; Hartung Hans-Peter
Mechanisms of mitoxantrone in multiple sclerosis--what is known?
Journal of the neurological sciences 2004;223(1):25-7.
2004: Saleh Andreas; Schroeter Michael; Jonkmanns Cornelia; Hartung Hans-Peter; Mödder Ulrich; Jander Sebastian
In vivo MRI of brain inflammation in human ischaemic stroke.
Brain : a journal of neurology 2004;127(Pt 7):1670-7.
2004: Hartung Hans-Peter; Munschauer Frederick E
Assessment and management of neutralizing antibodies in patients with multiple sclerosis.
Journal of neurology 2004;251 Suppl 2():II40-2.
2004: Wiendl H; Lehmann H C; Hohlfeld R; Hartung H-P; Kieseier B C
[Multiple sclerosis: potential therapeutic options and update of ongoing studies]
Der Nervenarzt 2004;75(6):536-52.
2004: Kieseier Bernd C; Archelos Juan J; Hartung Hans-Peter
Different effects of simvastatin and interferon beta on the proteolytic activity of matrix metalloproteinases.
Archives of neurology 2004;61(6):929-32.
2004: Neuhaus Oliver; Stüve Olaf; Zamvil Scott S; Hartung Hans-Peter
Are statins a treatment option for multiple sclerosis?
Lancet neurology 2004;3(6):369-71.
2004: Stüve Olaf; Prod'homme Thomas; Youssef Sawsan; Dunn Shannon; Neuhaus Oliver; Weber Martin; Hartung Hans-Peter; Steinman Lawrence; Zamvil Scott S
Statins as potential therapeutic agents in multiple sclerosis.
Current neurology and neuroscience reports 2004;4(3):237-44.
2004: Neuhaus O; Hartung H-P
[Neurological aspects of systemic rheumatological disorders]
Zeitschrift für Rheumatologie 2004;63(2):104-12.
2004: Jung Stefan; Gaupp Stefanie; Korn Thomas; Köllner Gabriele; Hartung Hans-Peter; Toyka Klaus V
Biphasic form of experimental autoimmune neuritis in dark Agouti rats and its oral therapy by antigen-specific tolerization.
Journal of neuroscience research 2004;75(4):524-35.
2004: Neuhaus Oliver; Kieseier Bernd C; Hartung Hans-Peter
Mitoxantrone (Novantrone) in multiple sclerosis: new insights.
Expert review of neurotherapeutics 2004;4(1):17-26.
2003: Hu Wei; Mathey Emily; Hartung Hans-Peter; Kieseier Bernd C
Cyclo-oxygenases and prostaglandins in acute inflammatory demyelination of the peripheral nerve.
Neurology 2003;61(12):1774-9.
2003: Lehmann Helmar C; Hartung Hans-Peter; Kieseier Bernd C
The prefaces of Charcot: leitmotifs of an international career.
Neurology 2003;61(8):1163; author reply 1163.
2003: Kieseier B C; Gold R; Hartung H-P
[Mitoxanthrone in the therapy of multiple sclerosis]
Der Nervenarzt 2003;74(10):906-10.
2003: Schroeter Michael; Stoll Guido; Weissert Robert; Hartung Hans-Peter; Lassmann Hans; Jander Sebastian
CD8+ phagocyte recruitment in rat experimental autoimmune encephalomyelitis: association with inflammatory tissue destruction.
The American journal of pathology 2003;163(4):1517-24.
2003: Neuhaus O; Wiendl H; Kieseier B C; Archelos J J; Hartung H-P
[Cholesterol-reducing medications-a new therapeutic option for multiple sclerosis? Statins as immunomodulators]
Der Nervenarzt 2003;74(8):704-7.
2003: Rosche B; Kieseier B; Hartung H-P; Hemmer B
[New understanding of the immunopathogenesis of multiple sclerosis]
Der Nervenarzt 2003;74(8):654-63.
2003: Paul Robert; Koedel Uwe; Winkler Frank; Kieseier Bernd C; Fontana Adriano; Kopf Manfred; Hartung H-P; Pfister H-W
Lack of IL-6 augments inflammatory response but decreases vascular permeability in bacterial meningitis.
Brain : a journal of neurology 2003;126(Pt 8):1873-82.
2003: Wiendl Heinz; Neuhaus Oliver; Mehling Matthias; Wintterle Sabine; Schreiner Bettina; Mitsdoerffer Meike; Wienhold Wolfgang; Weissert Robert; Wessels Johannes; Hartung Hans-Peter; Weller Michael; Tolosa Eva; Melms Arthur
The CD28 related molecule ICOS: T cell modulation in the presence and absence of B7.1/2 and regulational expression in multiple sclerosis.
Journal of neuroimmunology 2003;140(1-2):177-87.
2003: Kieseier Bernd C; Hartung Hans-Peter
Therapeutic strategies in the Guillain-Barré syndrome.
Seminars in neurology 2003;23(2):159-68.
2003: Kieseier Bernd C; Hartung Hans-Peter
Current disease-modifying therapies in multiple sclerosis.
Seminars in neurology 2003;23(2):133-46.
2003: Köller H; Kieseier B C; Jander S; Hartung H-P
[Acute and chronic inflammatory neuropathies--therapy]
Deutsche medizinische Wochenschrift (1946) 2003;128(25-26):1405-7.
2003: Köller H; Kieseier B C; Jander S; Hartung H-P
[Acute and chronic inflammatory neuropathies--diagnosis]
Deutsche medizinische Wochenschrift (1946) 2003;128(24):1357-60.
2003: Kieseier Bernd C; Pischel Heidrun; Neuen-Jacob Eva; Tourtellotte Wallace W; Hartung Hans-Peter
ADAM-10 and ADAM-17 in the inflamed human CNS.
Glia 2003;42(4):398-405.
2003: Hemmer Bernhard; Kieseier Bernd; Cepok Sabine; Hartung Hans-Peter
New immunopathologic insights into multiple sclerosis.
Current neurology and neuroscience reports 2003;3(3):246-55.
2003: Kastenbauer Stefan; Koedel Uwe; Wick Manfred; Kieseier Bernd C; Hartung Hans-Peter; Pfister Hans-Walter
CSF and serum levels of soluble fractalkine (CX3CL1) in inflammatory diseases of the nervous system.
Journal of neuroimmunology 2003;137(1-2):210-7.
2003: Auer-Grumbach Michaela; De Jonghe Peter; Verhoeven Kristien; Timmerman Vincent; Wagner Klaus; Hartung Hans-Peter; Nicholson Garth A
Autosomal dominant inherited neuropathies with prominent sensory loss and mutilations: a review.
Archives of neurology 2003;60(3):329-34.
2003: Neuhaus Oliver; Archelos Juan J; Hartung Hans-Peter
Immunomodulation in multiple sclerosis: from immunosuppression to neuroprotection.
Trends in pharmacological sciences 2003;24(3):131-8.
2003: Enzinger Christian; Ropele Stefan; Strasser-Fuchs Siegrid; Kapeller Peter; Schmidt Helena; Poltrum Birgit; Schmidt Reinhold; Hartung Hans-Peter; Fazekas Franz
Lower levels of N-acetylaspartate in multiple sclerosis patients with the apolipoprotein E epsilon4 allele.
Archives of neurology 2003;60(1):65-70.
2002: Hartung Hans-Peter; Gonsette Richard; König Nikolaus; Kwiecinski Hubert; Guseo Andreas; Morrissey Sean P; Krapf Hilmar; Zwingers Thomas;
Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, double-blind, randomised, multicentre trial.
Lancet 2002;360(9350):2018-25.
2002: Kieseier Bernd C; Dalakas Marinos C; Hartung Hans-Peter
Immune mechanisms in chronic inflammatory demyelinating neuropathy.
Neurology 2002;59(12 Suppl 6):S7-12.
2002: Seifert T; Kieseier B C; Ropele S; Strasser-Fuchs S; Quehenberger F; Fazekas F; Hartung H P
TACE mRNA expression in peripheral mononudear cells precedes new lesions on MRI in multiple sclerosis.
Multiple sclerosis (Houndmills, Basingstoke, England) 2002;8(6):447-51.
2002: Neuhaus O; Strasser-Fuchs S; Fazekas F; Kieseier B C; Niederwieser G; Hartung H P; Archelos J J
Statins as immunomodulators: comparison with interferon-beta 1b in MS.
Neurology 2002;59(7):990-7.
2002: Hemmer Bernhard; Archelos Juan J; Hartung Hans-Peter
New concepts in the immunopathogenesis of multiple sclerosis.
Nature reviews. Neuroscience 2002;3(4):291-301.
2002: Kieseier Bernd C; Tani Marie; Mahad Don; Oka Nobuyuki; Ho Tony; Woodroofe Nicola; Griffin John W; Toyka Klaus V; Ransohoff Richard M; Hartung Hans-Peter
Chemokines and chemokine receptors in inflammatory demyelinating neuropathies: a central role for IP-10.
Brain : a journal of neurology 2002;125(Pt 4):823-34.
2001: Fazekas F; Strasser-Fuchs S; Kollegger H; Berger T; Kristoferitsch W; Schmidt H; Enzinger C; Schiefermeier M; Schwarz C; Kornek B; Reindl M; Huber K; Grass R; Wimmer G; Vass K; Pfeiffer K H; Hartung H P; Schmidt R
Apolipoprotein E epsilon 4 is associated with rapid progression of multiple sclerosis.
Neurology 2001;57(5):853-7.
2001: Bammer R; Keeling S L; Augustin M; Pruessmann K P; Wolf R; Stollberger R; Hartung H P; Fazekas F
Improved diffusion-weighted single-shot echo-planar imaging (EPI) in stroke using sensitivity encoding (SENSE).
Magnetic resonance in medicine : official journal of the Society of Magnetic Resonance in Medicine / Society of Magnetic Resonance in Medicine 2001;46(3):548-54.
2001: Korn T; Toyka K; Hartung H P; Jung S
Suppression of experimental autoimmune neuritis by leflunomide.
Brain : a journal of neurology 2001;124(Pt 9):1791-802.
2001: Neuhaus O; Hartung H P
In search of a disease marker: the cytokine profile of primary progressive multiple sclerosis.
Multiple sclerosis (Houndmills, Basingstoke, England) 2001;7(3):143-4.
2001: Andorfer B; Kieseier B C; Mathey E; Armati P; Pollard J; Oka N; Hartung H P
Expression and distribution of transcription factor NF-kappaB and inhibitor IkappaB in the inflamed peripheral nervous system.
Journal of neuroimmunology 2001;116(2):226-32.
2001: Quasthoff S; Hartung H P
[Nerve growth factor (NGF) in treatment of diabetic polyneuropathy. One hope less?]
Der Nervenarzt 2001;72(6):456-9.
2001: Jung S; Gaupp S; Hartung H P; Toyka K V
Oral tolerance in experimental autoimmune neuritis (EAN) of the Lewis rat. II. Adjuvant effects and bystander suppression in P2 peptide-induced EAN.
Journal of neuroimmunology 2001;116(1):21-8.
2001: Krametter D; Niederwieser G; Berghold A; Birnbaum G; Strasser-Fuchs S; Hartung H P; Archelos J J
Chlamydia pneumoniae in multiple sclerosis: humoral immune responses in serum and cerebrospinal fluid and correlation with disease activity marker.
Multiple sclerosis (Houndmills, Basingstoke, England) 2001;7(1):13-8.
2001: Kieseier B C; Schneider C; Clements J M; Gearing A J; Gold R; Toyka K V; Hartung H P
Expression of specific matrix metalloproteinases in inflammatory myopathies.
Brain : a journal of neurology 2001;124(Pt 2):341-51.
2001: Krametter D; Niederwieser G; Berghold A; Birnbaum G; Strasser-Fuchs S; Hartung H P; Archelos J J
Chlamydia pneumoniae-specific humoral immune responses and clinical disease parameters in multiple sclerosis.
Annals of neurology 2001;49(1):135.
2000: Ropele S; Strasser-Fuchs S; Augustin M; Stollberger R; Enzinger C; Hartung H P; Fazekas F
A comparison of magnetization transfer ratio, magnetization transfer rate, and the native relaxation time of water protons related to relapsing-remitting multiple sclerosis.
AJNR. American journal of neuroradiology 2000;21(10):1885-91.
2000: Auer-Grumbach M; De Jonghe P; Wagner K; Verhoeven K; Hartung H P; Timmerman V
Phenotype-genotype correlations in a CMT2B family with refined 3q13-q22 locus.
Neurology 2000;55(10):1552-7.
2000: Roob G; Lechner A; Schmidt R; Flooh E; Hartung H P; Fazekas F
Frequency and location of microbleeds in patients with primary intracerebral hemorrhage.
Stroke; a journal of cerebral circulation 2000;31(11):2665-9.
2000: Augustin M; Bammer R; Simbrunner J; Stollberger R; Hartung H P; Fazekas F
Diffusion-weighted imaging of patients with subacute cerebral ischemia: comparison with conventional and contrast-enhanced MR imaging.
AJNR. American journal of neuroradiology 2000;21(9):1596-602.
2000: Bammer R; Augustin M; Strasser-Fuchs S; Seifert T; Kapeller P; Stollberger R; Ebner F; Hartung H P; Fazekas F
Magnetic resonance diffusion tensor imaging for characterizing diffuse and focal white matter abnormalities in multiple sclerosis.
Magnetic resonance in medicine : official journal of the Society of Magnetic Resonance in Medicine / Society of Magnetic Resonance in Medicine 2000;44(4):583-91.
2000: Kieseier B C; Krivacic K; Jung S; Pischel H; Toyka K V; Ransohoff R M; Hartung H P
Sequential expression of chemokines in experimental autoimmune neuritis.
Journal of neuroimmunology 2000;110(1-2):121-9.
2000: Auer-Grumbach M; Wagner K; Strasser-Fuchs S; Löscher W N; Fazekas F; Millner M; Hartung H P
Clinical predominance of proximal upper limb weakness in CMT1A syndrome.
Muscle & nerve 2000;23(8):1243-9.
2000: Auer-Grumbach M; Löscher W N; Wagner K; Petek E; Körner E; Offenbacher H; Hartung H P
Phenotypic and genotypic heterogeneity in hereditary motor neuronopathy type V: a clinical, electrophysiological and genetic study.
Brain : a journal of neurology 2000;123 ( Pt 8)():1612-23.
2000: Löscher W N; Auer-Grumbach M; Trinka E; Ladurner G; Hartung H P
Comparison of second lumbrical and interosseus latencies with standard measures of median nerve function across the carpal tunnel: a prospective study of 450 hands.
Journal of neurology 2000;247(7):530-4.
2000: Schmidt R; Schmidt H; Fazekas F; Kapeller P; Roob G; Lechner A; Kostner G M; Hartung H P
MRI cerebral white matter lesions and paraoxonase PON1 polymorphisms : three-year follow-up of the austrian stroke prevention study.
Arteriosclerosis, thrombosis, and vascular biology 2000;20(7):1811-6.
2000: Schmidt J; Gold R; Schönrock L; Zettl U K; Hartung H P; Toyka K V
T-cell apoptosis in situ in experimental autoimmune encephalomyelitis following methylprednisolone pulse therapy.
Brain : a journal of neurology 2000;123 ( Pt 7)():1431-41.
2000: Fazekas F; Strasser-Fuchs S; Schmidt H; Enzinger C; Ropele S; Lechner A; Flooh E; Schmidt R; Hartung H P
Apolipoprotein E genotype related differences in brain lesions of multiple sclerosis.
Journal of neurology, neurosurgery, and psychiatry 2000;69(1):25-8.
2000: Archelos J J; Hartung H P
Pathogenetic role of autoantibodies in neurological diseases.
Trends in neurosciences 2000;23(7):317-27.
2000: Hartung H P; Kieseier B C
The role of matrix metalloproteinases in autoimmune damage to the central and peripheral nervous system.
Journal of neuroimmunology 2000;107(2):140-7.
2000: Schneider C; Matsumoto Y; Kohyama K; Toyka K V; Hartung H P; Gold R
Experimental autoimmune myositis in the lewis rat: lack of spontaneous T-cell apoptosis and therapeutic response to glucocorticosteroid application.
Journal of neuroimmunology 2000;107(1):83-7.
2000: Archelos J J; Storch M K; Hartung H P
The role of B cells and autoantibodies in multiple sclerosis.
Annals of neurology 2000;47(6):694-706.
2000: Wohlleben G; Ibrahim S M; Schmidt J; Toyka K V; Hartung H P; Gold R
Regulation of Fas and FasL expression on rat Schwann cells.
Glia 2000;30(4):373-81.
2000: Bammer R; Fazekas F; Augustin M; Simbrunner J; Strasser-Fuchs S; Seifert T; Stollberger R; Hartung H P
Diffusion-weighted MR imaging of the spinal cord.
AJNR. American journal of neuroradiology 2000;21(3):587-91.
2000: Gold R; Hartung H P; Toyka K V
Animal models for autoimmune demyelinating disorders of the nervous system.
Molecular medicine today 2000;6(2):88-91.
2000: Auer-Grumbach M; Wagner K; Timmerman V; De Jonghe P; Hartung H P
Ulcero-mutilating neuropathy in an Austrian kinship without linkage to hereditary motor and sensory neuropathy IIB and hereditary sensory neuropathy I loci.
Neurology 2000;54(1):45-52.
2000: Kieseier B C; Storch M K; Hartung H P
Toxic effector molecules in the pathogenesis of immune-mediated disorders of the central nervous system.
Journal of neural transmission. Supplementum 2000;59():69-80.
1999: Roob G; Kleinert R; Seifert T; Lechner A; Kapeller P; Kleinert G; Schmidt R; Fazekas F; Hartung H P
[Indications of cerebral micro-hemorrhage in MRI. Comparative histological findings and possible clinical significance]
Der Nervenarzt 1999;70(12):1082-7.
1999: Auer-Grumbach M; Wagner K; Fazekas F; Löscher W N; Strasser-Fuchs S; Hartung H P
[Hereditary motor-sensory neuropathies (Charcot-Marie-Tooth syndrome) and related neuropathies. Current classification and genotype-phenotype correlation]
Der Nervenarzt 1999;70(12):1052-61.
1999: Gold R; Oelschläger M; Pepinsky R B; Sommer C; Hartung H P; Toyka K V
Increased lipocortin-1 (annexin-1) expression in the sciatic nerve of Lewis rats with experimental autoimmune neuritis.
Acta neuropathologica 1999;98(6):583-9.
1999: Ropele S; Stollberger R; Kapeller P; Hartung H P; Fazekas F
Fast multislice T(1) and t(1sat) imaging using a phase acquisition of composite echoes (PACE) technique.
Magnetic resonance in medicine : official journal of the Society of Magnetic Resonance in Medicine / Society of Magnetic Resonance in Medicine 1999;42(6):1089-97.
1999: Chan A; Gold R; Giegerich G; Herrmann T; Jung S; Toyka K V; Hartung H P
Usage of Vbeta3.3 T-cell receptor by myelin basic protein-specific encephalitogenic T-cell lines in the Lewis rat.
Journal of neuroscience research 1999;58(2):214-25.
1999: Auer-Grumbach M; Wagner K; Payer F; Hartung H P
Proximal Charcot-Marie-Tooth syndrome with duplication on chromosome 17p11.2.
Annals of the New York Academy of Sciences 1999;883():469-71.
1999: Zimmermann C; Walther E U; Goebels N; Lienert C; Kappos L; Hartung H P; Hohlfeld R
[Interferon beta-1b for treatment of secondary chronic progressive multiple sclerosis]
Der Nervenarzt 1999;70(8):759-63.
1999: Kieseier B C; Paul R; Koedel U; Seifert T; Clements J M; Gearing A J; Pfister H W; Hartung H P
Differential expression of matrix metalloproteinases in bacterial meningitis.
Brain : a journal of neurology 1999;122 ( Pt 8)():1579-87.
1999: Flachenecker P; Wolf A; Krauser M; Hartung H P; Reiners K
Cardiovascular autonomic dysfunction in multiple sclerosis: correlation with orthostatic intolerance.
Journal of neurology 1999;246(7):578-86.
1999: Auer-Grumbach M; Fazekas F; Radner H; Irmler A; Strasser-Fuchs S; Hartung H P
Troyer syndrome: a combination of central brain abnormality and motor neuron disease?
Journal of neurology 1999;246(7):556-61.
1999: Schmidt R; Fazekas F; Kapeller P; Schmidt H; Hartung H P
MRI white matter hyperintensities: three-year follow-up of the Austrian Stroke Prevention Study.
Neurology 1999;53(1):132-9.
1999: Kieseier B C; Seifert T; Giovannoni G; Hartung H P
Matrix metalloproteinases in inflammatory demyelination: targets for treatment.
Neurology 1999;53(1):20-5.
1999: Kieseier B C; Storch M K; Archelos J J; Martino G; Hartung H P
Effector pathways in immune mediated central nervous system demyelination.
Current opinion in neurology 1999;12(3):323-36.
1999: Kieseier B C; Clements J M; Gearing A J; Hartung H P
Matrix metalloproteinases exhibit different expression patterns in inflammatory demyelinating diseases of the central and peripheral nervous system.
Annals of the New York Academy of Sciences 1999;878():567-70.
1999: Kieseier B C; Seifert T; Hartung H P
[Matrix metalloproteinases. Potential targets for new treatments in inflammatory demyelinating diseases of the nervous system]
Der Nervenarzt 1999;70(6):509-16.
1999: Fazekas F; Kleinert R; Roob G; Kleinert G; Kapeller P; Schmidt R; Hartung H P
Histopathologic analysis of foci of signal loss on gradient-echo T2*-weighted MR images in patients with spontaneous intracerebral hemorrhage: evidence of microangiopathy-related microbleeds.
AJNR. American journal of neuroradiology 1999;20(4):637-42.
1999: Gold R; Archelos J J; Hartung H P
Mechanisms of immune regulation in the peripheral nervous system.
Brain pathology (Zurich, Switzerland) 1999;9(2):343-60.
1999: Thies F L; Karch H; Hartung H P; Giegerich G
The ClpB protein from Campylobacter jejuni: molecular characterization of the encoding gene and antigenicity of the recombinant protein.
Gene 1999;230(1):61-7.
1999: Roob G; Schmidt R; Kapeller P; Lechner A; Hartung H P; Fazekas F
MRI evidence of past cerebral microbleeds in a healthy elderly population.
Neurology 1999;52(5):991-4.
1999: Thies F L; Karch H; Hartung H P; Giegerich G
Cloning and expression of the dnaK gene of Campylobacter jejuni and antigenicity of heat shock protein 70.
Infection and immunity 1999;67(3):1194-200.
1999: Hartung H P; Flachenecker P; Weilbach F X; Rieckmann P
[PRISMS Study. Interferon-beta 1a (Rebif) in relapsing multiple sclerosis]
Der Nervenarzt 1999;70(2):182-5.
1999: Thies F L; Weishaupt A; Karch H; Hartung H P; Giegerich G
Cloning, sequencing and molecular analysis of the Campylobacter jejuni groESL bicistronic operon.
Microbiology (Reading, England) 1999;145 ( Pt 1)():89-98.
1999: Archelos J J; Previtali S C; Hartung H P
The role of integrins in immune-mediated diseases of the nervous system.
Trends in neurosciences 1999;22(1):30-8.
1999: Schneider C; Dalakas M C; Toyka K V; Said G; Hartung H P; Gold R
T-cell apoptosis in inflammatory neuromuscular disorders associated with human immunodeficiency virus infection.
Archives of neurology 1999;56(1):79-83.
1999: Roob G; Fazekas F; Hartung H P
Peripheral facial palsy: etiology, diagnosis and treatment.
European neurology 1999;41(1):3-9.
1999: Kieseier B C; Giovannoni G; Hartung H P
Immunological surrogate markers of disease activity in multiple sclerosis.
Electroencephalography and clinical neurophysiology. Supplement 1999;50():570-83.
1999: Wohlleben G; Hartung H P; Gold R
Humoral and cellular immune functions of cytokine-treated Schwann cells.
Advances in experimental medicine and biology 1999;468():151-6.
1998: Previtali S C; Archelos J J; Hartung H P
Expression of integrins in experimental autoimmune neuritis and Guillain-Barré syndrome.
Annals of neurology 1998;44(4):611-21.
1998: Schmidt H; Schmidt R; Niederkorn K; Gradert A; Schumacher M; Watzinger N; Hartung H P; Kostner G M
Paraoxonase PON1 polymorphism leu-Met54 is associated with carotid atherosclerosis: results of the Austrian Stroke Prevention Study.
Stroke; a journal of cerebral circulation 1998;29(10):2043-8.
1998: Thies F L; Hartung H P; Giegerich G
Cloning and expression of the Campylobacter jejuni lon gene detected by RNA arbitrarily primed PCR.
FEMS microbiology letters 1998;165(2):329-34.
1998: Archelos J J; Jung S; Rinner W; Lassmann H; Miyasaka M; Hartung H P
Role of the leukocyte-adhesion molecule L-selectin in experimental autoimmune encephalomyelitis.
Journal of the neurological sciences 1998;159(2):127-34.
1998: Enders U; Lobb R; Pepinsky R B; Hartung H P; Toyka K V; Gold R
The role of the very late antigen-4 and its counterligand vascular cell adhesion molecule-1 in the pathogenesis of experimental autoimmune neuritis of the Lewis rat.
Brain : a journal of neurology 1998;121 ( Pt 7)():1257-66.
1998: Kiefer R; Schweitzer T; Jung S; Toyka K V; Hartung H P
Sequential expression of transforming growth factor-beta1 by T-cells, macrophages, and microglia in rat spinal cord during autoimmune inflammation.
Journal of neuropathology and experimental neurology 1998;57(5):385-95.
1998: Fazekas F; Strasser-Fuchs S; Hartung H P
[Intravenous immunoglobulins in therapy of intermittent multiple sclerosis. An update]
Der Nervenarzt 1998;69(4):361-5.
1998: Kieseier B C; Clements J M; Pischel H B; Wells G M; Miller K; Gearing A J; Hartung H P
Matrix metalloproteinases MMP-9 and MMP-7 are expressed in experimental autoimmune neuritis and the Guillain-Barré syndrome.
Annals of neurology 1998;43(4):427-34.
1998: Kiefer R; Kieseier B C; Brück W; Hartung H P; Toyka K V
Macrophage differentiation antigens in acute and chronic autoimmune polyneuropathies.
Brain : a journal of neurology 1998;121 ( Pt 3)():469-79.
1998: Kieseier B C; Kiefer R; Clements J M; Miller K; Wells G M; Schweitzer T; Gearing A J; Hartung H P
Matrix metalloproteinase-9 and -7 are regulated in experimental autoimmune encephalomyelitis.
Brain : a journal of neurology 1998;121 ( Pt 1)():159-66.
1998: Archelos J J; Trotter J; Previtali S; Weissbrich B; Toyka K V; Hartung H P
Isolation and characterization of an oligodendrocyte precursor-derived B-cell epitope in multiple sclerosis.
Annals of neurology 1998;43(1):15-24.
1997: Weilbach F X; Hartung H P
[Physical trauma and multiple sclerosis]
Der Nervenarzt 1997;68(12):940-4.
1997: Walther E U; Dang T; Hartung H P; Hohlfeld R
[Formation of neutralizing antibodies in therapy of multiple sclerosis with interferon beta-1b. Practical procedure in suspected therapeutic failure]
Der Nervenarzt 1997;68(12):935-9.
1997: Jung S; Donhauser T; Toyka K V; Hartung H P
Propentofylline and iloprost suppress the production of TNF-alpha by macrophages but fail to ameliorate experimental autoimmune encephalomyelitis in Lewis rats.
Journal of autoimmunity 1997;10(6):519-29.
1997: Gaupp S; Hartung H P; Toyka K; Jung S
Modulation of experimental autoimmune neuritis in Lewis rats by oral application of myelin antigens.
Journal of neuroimmunology 1997;79(2):129-37.
1997: Previtali S C; Archelos J J; Hartung H P
Modulation of the expression of integrins on glial cells during experimental autoimmune encephalomyelitis. A central role for TNF-alpha.
The American journal of pathology 1997;151(5):1425-35.
1997: Archelos J J; Fortwängler T; Hartung H P
Attenuation of experimental autoimmune neuritis in the Lewis rat by treatment with an antibody to L-selectin.
Neuroscience letters 1997;235(1-2):9-12.
1997: Flachenecker P; Hartung H P; Reiners K
Power spectrum analysis of heart rate variability in Guillain-Barré syndrome. A longitudinal study.
Brain : a journal of neurology 1997;120 ( Pt 10)():1885-94.
1997: Weilbach F X; Jung S; Hartung H P; Toyka K V; Giegerich G
T-cell receptor V beta-element expression in peripheral nerves of Lewis rats suffering from experimental autoimmune neuritis.
Journal of neuroimmunology 1997;79(1):69-75.
1997: Flachenecker P; Wermuth P; Hartung H P; Reiners K
Quantitative assessment of cardiovascular autonomic function in Guillain-Barre syndrome.
Annals of neurology 1997;42(2):171-9.
1997: Archelos J J; Hartung H P
The role of adhesion molecules in multiple sclerosis: biology, pathogenesis and therapeutic implications.
Molecular medicine today 1997;3(7):310-21.
1997: Hartung H P; Hohlfeld R
[Interferon-beta 1a in therapy of relapsing-remitting multiple sclerosis]
Der Nervenarzt 1997;68(6):525-7.
1997: Enders U; Toyka K V; Hartung H P; Gold R
Failure of intravenous immunoglobulin (IVIg) therapy in experimental autoimmune neuritis (EAN) of the Lewis rat.
Journal of neuroimmunology 1997;76(1-2):112-6.
1997: Köller H; Siebler M; Hartung H P
Immunologically induced electrophysiological dysfunction: implications for inflammatory diseases of the CNS and PNS.
Progress in neurobiology 1997;52(1):1-26.
1997: Weishaupt A; Gold R; Gaupp S; Giegerich G; Hartung H P; Toyka K V
Antigen therapy eliminates T cell inflammation by apoptosis: effective treatment of experimental autoimmune neuritis with recombinant myelin protein P2.
Proceedings of the National Academy of Sciences of the United States of America 1997;94(4):1338-43.
1997: Fazekas F; Offenbacher H; Hartung H P
What is the role of ancillary investigations in establishing the diagnosis of multiple sclerosis?
European neurology 1997;38(4):255-7.
1997: Kieseier B C; Hartung H P
Matrix metalloproteinases in experimental autoimmune encephalomyelitis.
Advances in experimental medicine and biology 1997;421():303-6.
1997: Hartung H P; Rieckmann P
Pathogenesis of immune-mediated demyelination in the CNS.
Journal of neural transmission. Supplementum 1997;50():173-81.
1996: Schneider C; Gold R; Dalakas M C; Schmied M; Lassmann H; Toyka K V; Hartung H P
MHC class I-mediated cytotoxicity does not induce apoptosis in muscle fibers nor in inflammatory T cells: studies in patients with polymyositis, dermatomyositis, and inclusion body myositis.
Journal of neuropathology and experimental neurology 1996;55(12):1205-9.
1996: Gold R; Pepinsky R B; Zettl U K; Toyka K V; Hartung H P
Lipocortin-1 (annexin-1) suppresses activation of autoimmune T cell lines in the Lewis rat.
Journal of neuroimmunology 1996;69(1-2):157-64.
1996: Bourde O; Kiefer R; Toyka K V; Hartung H P
Quantification of interleukin-6 mRNA in wallerian degeneration by competitive reverse transcription polymerase chain reaction.
Journal of neuroimmunology 1996;69(1-2):135-40.
1996: Morrissey S P; Deichmann R; Syha J; Simonis C; Zettl U; Archelos J J; Jung S; Stodal H; Lassmann H; Toyka K V; Haase A; Hartung H P
Partial inhibition of AT-EAE by an antibody to ICAM-1: clinico-histological and MRI studies.
Journal of neuroimmunology 1996;69(1-2):85-93.
1996: Gold R; Zielasek J; Schröder J M; Sellhaus B; Cedarbaum J; Hartung H P; Sendtner M; Toyka K V
Treatment with ciliary neurotrophic factor does not improve regeneration in experimental autoimmune neuritis of the Lewis rat.
Muscle & nerve 1996;19(9):1177-80.
1996: Jung S; Toyka K; Hartung H P
T cell directed immunotherapy of inflammatory demyelination in the peripheral nervous system. Potent suppression of the effector phase of experimental autoimmune neuritis by anti-CD2 antibodies.
Brain : a journal of neurology 1996;119 ( Pt 4)():1079-90.
1996: Weilbach E X; Hartung H P
[Immune modulation in multiple sclerosis: linomide]
Der Nervenarzt 1996;67(8):701-5.
1996: Jung S; Zielasek J; Köllner G; Donhauser T; Toyka K; Hartung H P
Preventive but not therapeutic application of Rolipram ameliorates experimental autoimmune encephalomyelitis in Lewis rats.
Journal of neuroimmunology 1996;68(1-2):1-11.
1996: Flachenecker P; Müllges W; Wermuth P; Hartung H P; Reiners K
Eyeball pressure testing in the evaluation of serious bradyarrhythmias in Guillain-Barré syndrome.
Neurology 1996;47(1):102-8.
1996: Toyka K V; Hartung H P
Chronic inflammatory polyneuritis and neuropathies.
Current opinion in neurology 1996;9(3):240-50.
1996: Flachenecker P; Hartung H P
[Course of illness and prognosis of multiple sclerosis. 2: Predictive value of clinical and paraclinical factors]
Der Nervenarzt 1996;67(6):444-51.
1996: Flachenecker P; Hartung H P
[Course of illness and prognosis of multiple sclerosis. 1: The natural illness course]
Der Nervenarzt 1996;67(6):435-43.
1996: Hartung H P; Zielasek J; Jung S; Toyka K V
Effector mechanisms in demyelinating neuropathies.
Revue neurologique 1996;152(5):320-7.
1996: Gold R; Schmied M; Tontsch U; Hartung H P; Wekerle H; Toyka K V; Lassmann H
Antigen presentation by astrocytes primes rat T lymphocytes for apoptotic cell death. A model for T-cell apoptosis in vivo.
Brain : a journal of neurology 1996;119 ( Pt 2)():651-9.
1996: Flachenecker P; Hartung H P
[EDMUS--a new European databank for multiple sclerosis. A brief introduction of ongoing and planned multicenter studies within the scope of the "European Concentrated Action for Multiple Sclerosis"]
Der Nervenarzt 1996;67(4):277-82.
1996: Schmidt B; Toyka K V; Kiefer R; Full J; Hartung H P; Pollard J
Inflammatory infiltrates in sural nerve biopsies in Guillain-Barre syndrome and chronic inflammatory demyelinating neuropathy.
Muscle & nerve 1996;19(4):474-87.
1996: Morrissey S P; Stodal H; Zettl U; Simonis C; Jung S; Kiefer R; Lassmann H; Hartung H P; Haase A; Toyka K V
In vivo MRI and its histological correlates in acute adoptive transfer experimental allergic encephalomyelitis. Quantification of inflammation and oedema.
Brain : a journal of neurology 1996;119 ( Pt 1)():239-48.
1996: Gold R; Zielasek J; Kiefer R; Toyka K V; Hartung H P
Secretion of nitrite by Schwann cells and its effect on T-cell activation in vitro.
Cellular immunology 1996;168(1):69-77.
1996: Stangel M; Zettl U K; Mix E; Zielasek J; Toyka K V; Hartung H P; Gold R
H2O2 and nitric oxide-mediated oxidative stress induce apoptosis in rat skeletal muscle myoblasts.
Journal of neuropathology and experimental neurology 1996;55(1):36-43.
1996: Kiefer R; Funa K; Schweitzer T; Jung S; Bourde O; Toyka K V; Hartung H P
Transforming growth factor-beta 1 in experimental autoimmune neuritis. Cellular localization and time course.
The American journal of pathology 1996;148(1):211-23.
1996: Hartung H P
[Pathogenesis of multiple sclerosis: status of research]
Wiener medizinische Wochenschrift (1946) 1996;146(19-20):520-7.
1996: Hartung H P; Willison H; Jung S; Pette M; Toyka K V; Giegerich G
Autoimmune responses in peripheral nerve.
Springer seminars in immunopathology 1996;18(1):97-123.
1996: Zetti U K; Gold R; Toyka K V; Hartung H P
In situ demonstration of T cell activation and elimination in the peripheral nervous system during experimental autoimmune neuritis in the Lewis rat.
Acta neuropathologica 1996;91(4):360-7.
1996: Zielasek J; Hartung H P
Molecular mechanisms of microglial activation.
Advances in neuroimmunology 1996;6(2):191-22.
1995: Weishaupt A; Giegerich G; Jung S; Gold R; Enders U; Pette M; Hayasaka K; Hartung H P; Toyka K V
T cell antigenic and neuritogenic activity of recombinant human peripheral myelin P2 protein.
Journal of neuroimmunology 1995;63(2):149-56.
1995: Jung S; Toyka K V; Hartung H P
Soluble complement receptor type 1 inhibits experimental autoimmune neuritis in Lewis rats.
Neuroscience letters 1995;200(3):167-70.
1995: Flachenecker P; Toyka K V; Hartung H P
[Active vaccinations in multiple sclerosis]
Deutsche medizinische Wochenschrift (1946) 1995;120(44):1513-6.
1995: Gold R; Toyka K V; Hartung H P
Synergistic effect of IFN-gamma and TNF-alpha on expression of immune molecules and antigen presentation by Schwann cells.
Cellular immunology 1995;165(1):65-70.
1995: Weilbach F X; Toyka K V; Hartung H P
[Oral, low-dosage methotrexate in chronic progressive multiple sclerosis. A preliminary critical analysis]
Der Nervenarzt 1995;66(8):643-7.
1995: Hartung H P; Reiners K; Archelos J J; Michels M; Seeldrayers P; Heidenreich F; Pflughaupt K W; Toyka K V
Circulating adhesion molecules and tumor necrosis factor receptor in multiple sclerosis: correlation with magnetic resonance imaging.
Annals of neurology 1995;38(2):186-93.
1995: Zettl U K; Gold R; Toyka K V; Hartung H P
Intravenous glucocorticosteroid treatment augments apoptosis of inflammatory T cells in experimental autoimmune neuritis (EAN) of the Lewis rat.
Journal of neuropathology and experimental neurology 1995;54(4):540-7.
1995: Hartung H P; Archelos J J; Zielasek J; Gold R; Koltzenburg M; Reiners K H; Toyka K V
Circulating adhesion molecules and inflammatory mediators in demyelination: a review.
Neurology 1995;45(6 Suppl 6):S22-32.
1995: Gold R; Giegerich G; Hartung H P; Toyka K V
T-cell receptor (TCR) usage in Lewis rat experimental autoimmune encephalomyelitis: TCR beta-chain-variable-region V beta 8.2-positive T cells are not essential for induction and course of disease.
Proceedings of the National Academy of Sciences of the United States of America 1995;92(13):5850-4.
1995: Pette M; Gold R; Pette D F; Hartung H P; Toyka K V
Mafosfamide induces DNA fragmentation and apoptosis in human T-lymphocytes. A possible mechanism of its immunosuppressive action.
Immunopharmacology 1995;30(1):59-69.
1995: Weilbach F X; Voltz R; Hohlfeld R; Hartung H P
[Copolymer 1 in therapy of multiple sclerosis]
Der Nervenarzt 1995;66(6):473-7.
1995: Jung S; Toyka K; Hartung H P
Suppression of experimental autoimmune encephalomyelitis in Lewis rats by antibodies against CD2.
European journal of immunology 1995;25(5):1391-8.
1995: Weilbach F X; Hartung H P
[Cladribine in chronic progressive multiple sclerosis]
Der Nervenarzt 1995;66(4):299-303.
1995: Harvey G K; Toyka K V; Zielasek J; Kiefer R; Simonis C; Hartung H P
Failure of anti-GM1 IgG or IgM to induce conduction block following intraneural transfer.
Muscle & nerve 1995;18(4):388-94.
1995: Zielasek J; Jung S; Gold R; Liew F Y; Toyka K V; Hartung H P
Administration of nitric oxide synthase inhibitors in experimental autoimmune neuritis and experimental autoimmune encephalomyelitis.
Journal of neuroimmunology 1995;58(1):81-8.
1995: Hartung H P; Pollard J D; Harvey G K; Toyka K V
Immunopathogenesis and treatment of the Guillain-Barré syndrome--Part II.
Muscle & nerve 1995;18(2):154-64.
1995: Hartung H P; Pollard J D; Harvey G K; Toyka K V
Immunopathogenesis and treatment of the Guillain-Barré syndrome--Part I.
Muscle & nerve 1995;18(2):137-53.
1995: Flachenecker P; Hartung H P
[Multiple sclerosis and pregnancy. Overview and status of the European multicenter PRIMS study]
Der Nervenarzt 1995;66(2):97-104.
1995: Gold R; Hartung H P; Toyka K V
[Therapy with immunoglobulins in neurologic autoimmune diseases. Indications and mechanism of action]
Fortschritte der Neurologie-Psychiatrie 1995;63(1):17-29.
1995: Zielasek J; Reichmann H; Künzig H; Jung S; Hartung H P; Toyka K V
Inhibition of brain macrophage/microglial respiratory chain enzyme activity in experimental autoimmune encephalomyelitis of the Lewis rat.
Neuroscience letters 1995;184(2):129-32.
1995: Stangel M; Giegerich G; Torres-Nagel N E; Hünig T; Hartung H P
Structural analysis of the rat T-cell receptor Tcra V4 gene family.
Immunogenetics 1995;41(2-3):125-30.
1994: Pette M; Hartung H P; Toyka K V
[Immune augmenting therapy as treatment of multiple sclerosis. Warning regarding a potentially toxic alternative treatment method]
Der Nervenarzt 1994;65(12):878-90.
1994: Hartung H P; Gold R; Zielasek J; Archelos J J; Toyka K V
[Therapy of acute polyradiculoneuritis (Guillain-Barré syndrome)]
Der Nervenarzt 1994;65(12):807-18.
1994: Jung S; Schluesener H J; Schmidt B; Fontana A; Toyka K V; Hartung H P
Therapeutic effect of transforming growth factor-beta 2 on actively induced EAN but not adoptive transfer EAN.
Immunology 1994;83(4):545-51.
1994: Jung S; Toyka K V; Hartung H P
Impact of 15-deoxyspergualin on effector cells in experimental autoimmune diseases of the nervous system in the Lewis rat.
Clinical and experimental immunology 1994;98(3):494-502.
1994: Pette M; Linington C; Gengaroli C; Grosse-Wilde H; Toyka K V; Hartung H P
T lymphocyte recognition sites on peripheral nerve myelin P0 protein.
Journal of neuroimmunology 1994;54(1-2):29-34.
1994: Gold R; Schmied M; Giegerich G; Breitschopf H; Hartung H P; Toyka K V; Lassmann H
Differentiation between cellular apoptosis and necrosis by the combined use of in situ tailing and nick translation techniques.
Laboratory investigation; a journal of technical methods and pathology 1994;71(2):219-25.
1994: Stangel M; Toyka K V; Hartung H P; Giegerich G
Bacterial expression of a soluble T-cell receptor alpha chain.
Biochemical and biophysical research communications 1994;202(3):1280-4.
1994: Harvey G K; Toyka K V; Hartung H P
Effects of mast cell degranulation on blood-nerve barrier permeability and nerve conduction in vivo.
Journal of the neurological sciences 1994;125(1):102-9.
1994: Zettl U K; Gold R; Hartung H P; Toyka K V
Apoptotic cell death of T-lymphocytes in experimental autoimmune neuritis of the Lewis rat.
Neuroscience letters 1994;176(1):75-9.
1994: Zielasek J; Ritter G; Magi S; Hartung H P; Toyka K V
A comparative trial of anti-glycoconjugate antibody assays: IgM antibodies to GM1.
Journal of neurology 1994;241(8):475-80.
1994: Hartung H P; Reiners K; Michels M; Hughes R A; Heidenreich F; Zielasek J; Enders U; Toyka K V
Serum levels of soluble E-selectin (ELAM-1) in immune-mediated neuropathies.
Neurology 1994;44(6):1153-8.
1994: Pette M; Gengaroli C; Hartung H P; Greiner A; Giegerich G; Toyka K V
Human T lymphocytes distinguish bovine from human P2 peripheral myelin protein: implications for immunological studies on inflammatory demyelinating neuropathies.
Journal of neuroimmunology 1994;52(1):47-52.
1994: Archelos J J; Mäurer M; Jung S; Miyasaka M; Tamatani T; Toyka K V; Hartung H P
Inhibition of experimental autoimmune neuritis by an antibody to the lymphocyte function-associated antigen-1.
Laboratory investigation; a journal of technical methods and pathology 1994;70(5):667-75.
1994: Pette M; Hartung H P; Toyka K V
[Cyclophosphamide in therapy of chronic progressive multiple sclerosis. Critical analysis of current studies]
Der Nervenarzt 1994;65(4):271-4.
1994: Hartung H P; Hohlfeld R
[Interferon-beta in treatment of relapsing multiple sclerosis]
Der Nervenarzt 1994;65(2):139-45.
1994: Hartung H P
Experimental allergic neuritis and Guillain-Barré syndrome: immune mechanisms. A short review.
Acta neurologica Belgica 1994;94(2):120-3.
1993: Jung S; Huitinga I; Schmidt B; Zielasek J; Dijkstra C D; Toyka K V; Hartung H P
Selective elimination of macrophages by dichlormethylene diphosphonate-containing liposomes suppresses experimental autoimmune neuritis.
Journal of the neurological sciences 1993;119(2):195-202.
1993: Hartung H P; Michels M; Reiners K; Seeldrayers P; Archelos J J; Toyka K V
Soluble ICAM-1 serum levels in multiple sclerosis and viral encephalitis.
Neurology 1993;43(11):2331-5.
1993: Pette M; Liebert U G; Göbel U; Grosse-Wilde H; Hartung H P; Toyka K V
Measles virus-directed responses of CD4+ T lymphocytes in MS patients and healthy individuals.
Neurology 1993;43(10):2019-25.
1993: Archelos J J; Mäurer M; Jung S; Toyka K V; Hartung H P
Suppression of experimental allergic neuritis by an antibody to the intracellular adhesion molecule ICAM-1.
Brain : a journal of neurology 1993;116 ( Pt 5)():1043-58.
1993: Enders U; Karch H; Toyka K V; Michels M; Zielasek J; Pette M; Heesemann J; Hartung H P
The spectrum of immune responses to Campylobacter jejuni and glycoconjugates in Guillain-Barré syndrome and in other neuroimmunological disorders.
Annals of neurology 1993;34(2):136-44.
1993: Archelos J J; Jung S; Mäurer M; Schmied M; Lassmann H; Tamatani T; Miyasaka M; Toyka K V; Hartung H P
Inhibition of experimental autoimmune encephalomyelitis by an antibody to the intercellular adhesion molecule ICAM-1.
Annals of neurology 1993;34(2):145-54.
1993: Seeldrayers P A; Syha J; Morrissey S P; Stodal H; Vass K; Jung S; Gneiting T; Lassmann H; Haase A; Hartung H P
Magnetic resonance imaging investigation of blood-brain barrier damage in adoptive transfer experimental autoimmune encephalomyelitis.
Journal of neuroimmunology 1993;46(1-2):199-206.
1993: Archelos J J; Roggenbuck K; Schneider-Schaulies J; Toyka K V; Hartung H P
Detection and quantification of antibodies to the extracellular domain of P0 during experimental allergic neuritis.
Journal of the neurological sciences 1993;117(1-2):197-205.
1993: Hartung H P
Immune-mediated demyelination.
Annals of neurology 1993;33(6):563-7.
1993: Jung S; Schluesener H J; Toyka K V; Hartung H P
Modulation of EAE by vaccination with T cell receptor peptides: V beta 8 T cell receptor peptide-specific CD4+ lymphocytes lack direct immunoregulatory activity.
Journal of neuroimmunology 1993;45(1-2):15-22.
1993: Archelos J J; Roggenbuck K; Schneider-Schaulies J; Linington C; Toyka K V; Hartung H P
Production and characterization of monoclonal antibodies to the extracellular domain of P0.
Journal of neuroscience research 1993;35(1):46-53.
1993: Zielasek J; Archelos J J; Toyka K V; Hartung H P
Expression of intercellular adhesion molecule-1 on rat microglial cells.
Neuroscience letters 1993;153(2):136-9.
1993: Zielasek J; Jung S; Schmidt B; Ritter G; Hartung H P; Toyka K
Effects of ganglioside administration on experimental autoimmune neuritis induced by peripheral nerve myelin or P2-specific T cell lines.
Journal of neuroimmunology 1993;43(1-2):103-11.
1992: Hartung H P; Jung S; Stoll G; Zielasek J; Schmidt B; Archelos J J; Toyka K V
Inflammatory mediators in demyelinating disorders of the CNS and PNS.
Journal of neuroimmunology 1992;40(2-3):197-210.
1992: Jung S; Krämer S; Schluesener H J; Hünig T; Toyka K; Hartung H P
Prevention and therapy of experimental autoimmune neuritis by an antibody against T cell receptors-alpha/beta.
Journal of immunology (Baltimore, Md. : 1950) 1992;148(12):3768-75.
1992: Zielasek J; Tausch M; Toyka K V; Hartung H P
Production of nitrite by neonatal rat microglial cells/brain macrophages.
Cellular immunology 1992;141(1):111-20.
1991: Jung S; Schluesener H J; Toyka K; Hartung H P
T cell vaccination does not induce resistance to experimental autoimmune neuritis.
Journal of neuroimmunology 1991;35(1-3):1-11.
1991: Hartung H P; Reiners K; Schmidt B; Stoll G; Toyka K V
Serum interleukin-2 concentrations in Guillain-Barré syndrome and chronic idiopathic demyelinating polyradiculoneuropathy: comparison with other neurological diseases of presumed immunopathogenesis.
Annals of neurology 1991;30(1):48-53.
1990: Hartung H P; Toyka K V
T-cell and macrophage activation in experimental autoimmune neuritis and Guillain-Barré syndrome.
Annals of neurology 1990;27 Suppl():S57-63.

Sign-in to see more